NCT05382364
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients who have not progressed on at least one previous therapeutic regimen; Patients with symptomatic central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT05382364